
TNF TNF

13.1.1

TNF TNF
/ 1 0.8mg/kg 50mg/ 2 0.4mg/kg
25mg 2
JIA

13.1.2 Infliximab

Infliximab
/ 8 1 6mg/kg
3mg/kg/
Infliximab

13.1.3

/ 2 1 24mg/m2/ 40mg/
A

13.2

13.2.1 Abatacept

Abatacept T CTL4Ig

Abatacept 1-6mg/kg
Abatacept
TNF

13.2.2 Anakinra

Anakinra IL-1 IL-1
cryopirin CAPS
Anakinra 1-2mg/kg
5mg/kg 100mg
JIA
cryopirin CAPS

13.2.3 Canakinumab

Canakinumab 1 (IL1)
cryopirin (CAPS)
Canakinumab 1-4mg/kg
cryopirin (CAPS)

13.2.4

6 IL6
JIA 15-30kg 1-8mg/kg
30kg 12mg/kg 4-10mg/kg
JIA
JIA

13.3

rituximab (anti-CD20) tofacitinib (JAK-3 inhibitor) and other immunosuppressants. The use of these drugs is associated with an increased risk of infection, including opportunistic infections and reactivation of latent viruses. Patients should be monitored for signs and symptoms of infection, and should avoid contact with sick individuals and crowded places. Live vaccines should be avoided while on these medications.